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ABSTRACT
Objective To examine the influence of age on the
predictive value of N-terminal pro-brain natriuretic (NT-
proBNP) peptide assay in acute myocardial infarction.
Design Prospective observational study.
Setting All intensive care units in one French region.
Participants 3291 consecutive patients admitted for an
acute myocardial infarction, from the RICO survey (a
French regional survey for acute myocardial infarction).
Main outcome measure Cardiovascular death at 1 year.
Results Among the 3291 participants, mean age was 68
(SD 14) years and 2356 (72%) were men. In the study
population, the median NT-proBNP concentration was
1053 (interquartile range 300-3472) pg/ml. Median
values for age quarters 1 to 4 were 367 (119-1050), 696
(201-1950), 1536 (534-4146), and 3774 (1168-9724)
pg/ml(P<0.001).Amultiplelinearregressionanalysiswas
done to determine the factors associated with the pro-
peptide concentrations in the overall population. NT-
proBNP was mainly associated with age, left ventricular
ejection fraction, creatinine clearance, female sex,
hypertension, diabetes, and anterior wall infarction. At
oneyear’sfollow-up,384(12%)patientshaddiedfromall
causes and 372 (11%) from cardiovascular causes. In
multivariate analysis, NT-proBNP remained strongly
associated with the outcome, beyond traditional risk
factors including creatinine clearance and left ventricular
ejectionfraction,ineachagegroupexceptintheyoungest
one (<54 years) (P=0.29). The addition of NT-proBNP
significantly improved the performance of the statistical
model in the overall study population (−2log likelihood
3179.58 v 3099.74, P<0.001) and in each age quarter
including the upper one (1523.52 v 1495.01, P<0.001).
The independent discriminative value of NT-proBNP
compared with the GRACE score was tested by a diagonal
stratification using the median value of the GRACE score
and NT-proBNP in older patients (upper quarter). Such
stratification strikingly identified a high risk group—
patientsfromthehigherNT-proBNPgroupandwithahigh
riskscore—characterisedbyariskofdeathofalmost50%
at one year.
Conclusions In this large contemporary non-selected
cohort of patients with myocardial infarction, NT-proBNP
concentration had incremental prognostic value even in
the oldest patients, above and beyond the GRACE risk
score and traditional biomarkers after acute myocardial
infarction. These data further support the potential
interest of clinical trials specifically assessing NT-proBNP
measurement as a guide to current treatment strategies,
as well as novel strategies, in older patients with acute
myocardial infarction.
INTRODUCTION
The number of older people with acute myocardial
infarction has increased in the past two decades.
1
Although mortality after myocardial infarction has
decreased over time in older patients, it has remained
markedly higher than in younger patients.
2 Moreover,
although older patients have a much higher rate of
comorbiditiesandaretreatedlessvigorously,ageitself
has been found to be an independent risk factor after
myocardial infarction.
34 This emphasises the impor-
tanceofdeterminingsuitabletoolsforriskstratification
in older patients after myocardial infarction.
5 B-type
natriuretic peptide (77-108 amino acids) and its N-
terminal (1-76 amino acids) counterpart (N-terminal
pro-brain natriuretic peptide or NT-proBNP) are
secretedfromcardiomyocytesinresponsetoincreased
walltension.
67Bothnatriureticpeptideshaveemerged
as major prognostic factors for short term and long
term mortalityacrossthe whole spectrumofacute cor-
onary syndromes and beyond traditional risk
markers.
89 Among factors that potentially affect
plasma B-type natriuretic peptide, older age and
altered left ventricular ejection fraction profoundly
increase the circulating concentration.
10-12 B-type
natriuretic peptide concentrations have been shown
to add to the prognostic information in patients with
myocardial infarction and left ventricular
dysfunction.
13 However, few studies have examined
the prognostic information derived from the B-type
natriuretic peptide concentration in older patients.
14
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patients with acute myocardial infarction, this study
aimedtoinvestigatethe influenceofageonthepredic-
tive value for mortality of concentrations of NT-
proBNP at admission to hospital.
METHODS
Patient population
We recruited the participants in this study from the
RICO (observatoire des infarctus de Côte-d’Or) sur-
vey, a French regional survey for acute myocardial
infarction. Briefly, the population based RICO survey
collects in-hospital data from consecutive patients
admitted for acute myocardial infarction in all public
centres or privately funded hospitals of one eastern
region of France.
15 In the study reported here, we
included patients admitted to one of the aforemen-
tionedcentresbetween1January2001and31Decem-
ber 2006 with acute myocardial infarction within 12
hours after onset of symptoms. Myocardial infarction
was diagnosed according to European Society of
Cardiology and American College of Cardiology
criteria.
16
Data collection
We collected data on patients’ age, sex, and cardio-
vascularriskfactors(historyofhypertensionortreated
hypertension, known history of diabetes, treated
hypercholesterolaemia,bodymassindex(kg/m
2),cur-
rent smoking (reported active smoking of cigarettes
within three months before this admission)). We
defined previous myocardial infarction as at least one
myocardial infarction before the admission. We also
collecteddataonhaemodynamicparametersatadmis-
sion (heart rate, systolic and diastolic blood pressure)
andKillipclass:Killip1—noclinicalsignsofheartfail-
ure, Killip2—heartfailure (rales in lungs(up to50% of
lungfields),S3gallop,orelevatedjugularvenouspres-
sure consistent with heart failure), Killip 3—severe
heart failure (pulmonary oedema with rales in >50%
of lung fields), Killip 4—cardiogenic shock. Patients
were diagnosed as having ST segment elevation myo-
cardialinfarctionwhentheyhadneworpresumednew
ST segment elevation greater than 1 mm seen in any
location or new left bundle branch block on the index
or subsequent electrocardiogram. Left ventricular
ejection fraction was measured by echocardiography
at day 3±1 after admission with the Simpson method
anddichotomisedat40%forgreaterclinicalrelevance.
We calculated the Global Registry of Acute Coron-
ary Events (GRACE) risk score with admission vari-
ables including age, heart rate, serum creatinine,
systolic blood pressure, Killip class, cardiac arrest, ST
segment deviation, and cardiac markers (www.out
comes-umassmed.org/grace/acs_risk.cfm).
17 The
GRACE risk model has shown excellent characteris-
tics as a predictor of mortality, providing most (>90%)
of the prognostic information. We obtained informa-
tion on cardiovascular mortality at one year’s follow-
up(mean310(SD113)days)bytelephoneinterviewor
mail from the patient, the patient’s relatives, or the
treatingphysician.Oneyearoffollow-upwasachieved
in 3225 (98%) patients. Each patient gave written con-
sent before participation.
Laboratory analysis
Blood samples for measurement of concentrations of
NT-proBNP, C reactive protein, and creatinine were
collected on admission in tubes containing EDTA.
Median time from onset of symptoms to blood sam-
pling was 160 (interquartile range 85-466) minutes.
We determined plasma NT-proBNP concentrations
by electrochemiluminescence immunoassay (Elecsys
2010, Roche Diagnostics). The inter-assay and intra-
assay coefficients of variation were both less than
3.1%. The sensitivity of the assay was 0.6 pmol/l. The
cross reactivity with other natriuretic peptides (B-type
natriuretic peptide, atrial natriuretic peptide, and C-
type natriuretic peptide) was <0.01%. We measured
C reactive protein with a dimension Xpand (Dade
Behring, Newark, NE) and creatinine with a Vittos
950 analyser (Ortho Clinical Diagnostics, Rochester,
NY).WeusedtheCockcroft-Gaultformulatoestimate
serumcreatinineclearance.
18Weassessedpeakplasma
troponin Ic by sampling every eight hours during the
first two days after admission (Dimension Vista Intel-
ligent Lab System, Siemens).
Statistical analysis
We divided the patients into quarters on the basis of
theirage.Weusedtheχ²testfortrendtocomparecate-
gorical variables across the quarters. For continuous
variables, we used the Kolmogorov-Smirnov test to
check the normality of the distribution and compared
the variables by either one way analysis of variance or
Kruskal-Wallis one way analysis, as appropriate. We
did a multiple linear regression analysis to determine
the factors that were associated with the pro-peptide
concentrations. Variables that were significantly asso-
ciatedinunivariateanalysiswereintroducedascovari-
atesinthemultipleregressionmodel.Beforedoingthe
multivariable linear regression analysis, we tested the
nature of the relation with log NT-proBNP with and
without log transformation of each non-normally dis-
tributed variable. We chose the expression of the data
(log transformed or not) that gave the best fitting of
linearityforintroductionintothemodel.Leftventricu-
lar ejection fraction was log transformed.
We used multivariate Cox regression analysis to
identifyindependentpredictorsofcardiovascularmor-
tality at one year. We tested all the variables listed in
table 1inunivariateanalysisandintroducedtheminto
the multivariate model if the P value was <0.10. Vari-
ables associated with the prognosis were sex, age,
hypertension,previousmyocardialinfarction,leftven-
tricular ejectionfraction <40%, Killip class >1,C reac-
tive protein >3 mg/l, peak troponin >100 upper limit
ofnormal,heartrate,creatinineclearance<30ml/min,
diabetesmellitus,andGRACEriskscore.Weincluded
these as covariates in the multivariate analysis, either
withoutorwithNT-proBNP,adjustedforsex,previous
myocardialinfarction, left ventricular ejectionfraction
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ponin >100 upper limit of normal, and GRACE score
(table 2). As age is a potential confounder of the rela-
tion between NT-proBNP and outcome, we tested its
interaction in univariate analysis and as a covariate in
multivariateanalysis.Thegoodnessofthefitwastested
bythe−2loglikelihoodχ²criterion.Wetestedtheaddi-
tional prognostic information from NT-proBNP in
each quarter by comparing the −2log likelihoods of
the model. We used the SPSS 13.0 software package
for all analyses.
RESULTS
Amongthe3291participants,themeanagewas68(SD
14) years and 2356 (72%) were men. Table 1 lists the
baseline characteristics categorised by age quarters. In
thestudypopulation,themedianNT-proBNPconcen-
trationwas1053(interquartilerange300-3472)pg/ml.
Median values in quarters 1 to 4 were 367 (119-1050),
696 (201-1950), 1536 (534-4146), and 3774 (1168-
9724)pg/ml(P<0.001).Multiplelinearregressionana-
lysis showed that NT-proBNP concentration was
mainly associated with age (β=0.010, P<0.001), left
ventricular ejection fraction (β=−1.628, P<0.001),
creatinine clearance (β=−0.939, P<0.001), female sex
(β=0.151, P<0.001), hypertension (β=0.104, P<0.001),
diabetes (β=0.062, P=0.031), and anterior wall infarc-
tion (β=0.089, P<0.001).
Atoneyear’sfollow-up,384(12%)patientshaddied
from all causes and 372 (11%) from cardiovascular
Table 1 |Characteristics of study population divided by age. Values are numbers (percentages) unless stated otherwise
Characteristics
Quarter (age)
P value 1( n =822) 2 (n=823) 3 (n=823) 4 (n=823)
Age (years):
Median 47 61 73 82
Interquartile range 43-51 57-64 70-75 79-85
Range 20-54 54-68 68-77 77-103
Male 693 (84) 676 (82) 559 (68) 428 (52) 0.001
Hypertension 241 (29) 421 (51) 525 (64) 561 (68) 0.001
Diabetes 76 (9) 177 (22) 231 (28) 259 (31) 0.001
Dyslipidaemia 350 (42) 425 (52) 402 (49) 305 (37) 0.001
Current smoker 559 (68) 272 (33) 89 (11) 36 (4) 0.001
Previous myocardial infarction 61 (7) 101 (12) 117 (14) 163 (20) 0.001
Median (interquartile range) body
mass index (kg/m²)
26 (24-30) 27 (24-30) 27 (24-29) 25 (23-28) 0.001
ST segment elevation myocardial
infarction
529 (64) 483 (59) 452 (55) 458 (56) 0.001
Anterior wall location 316 (38) 305 (37) 314 (38) 271 (33) 0.075
Median(interquartilerange)creatinine
clearance (ml/min)
108 (88-126) 87 (71-105) 63 (50-76) 44 (33-57) 0.001
Median (interquartile range) NT-
proBNP (pg/ml)
367 (119-1050) 696 (201-1950) 1536 (534-4146) 3774 (1168-9724) 0.001
Median (interquartilerange) C reactive
protein (mg/l)
4.66 (2-11) 6.3 (2.4-18.5) 6.8 (2.5-23) 10.7 (3.6-39.9) 0.001
Median (interquartile range) heart rate
(beat/min)
76 (65-88) 76 (65-90) 78 (66-91) 80 (67-94) 0.001
Killip class >1 110 (13) 173 (21) 292 (35) 414 (50) 0.001
Median (interquartile range) LVEF (%) 59 (50-65) 55 (45-63) 52 (42-63) 48 (38-57) 0.001
Median (interquartile range) GRACE
score
107 (89-126) 129 (108-147) 154 (133-174) 171 (150-196) <0.001
Troponin >100 upper limit of normal 516 (63) 491 (60) 470 (57) 474 (58) 0.086
Cardiac arrest 64 (8) 49 (6) 41 (5) 32 (4) 0.005
GRACE=Global Registry of Acute Coronary Events; LVEF=left ventricular ejection fraction; NT-proBNP=N-terminal proB-type natriuretic peptide.
Table 2 |Predictor of one year cardiovascular mortality by Cox regression analysis
Quarter (age) Cardiovascular death—No (%)
Unadjusted hazard ratio (95%
CI) P value Adjustedhazardratio*(95%CI) P value
Overall 372/3291 (11.3) 2.55 (1.99 to 3.26) <0.001 2.82 (2.22 to 3.59) <0.001
Q1 25/822 (3.0) 1.77 (0.61 to 5.13) 0.29 1.45 (0.52 to 3.88) 0.50
Q2 45/823 (5.5) 5.11 (2.42 to 10.81) <0.001 4.52 (2.05 to 9.98) <0.001
Q3 103/823 (12.5) 2.53 (1.61 to 3.98) <0.001 1.92 (1.24 to 2.98) 0.003
Q4 199/823 (24.2) 2.34 (1.66 to 3.29) <0.001 2.55 (1.79 to 3.64) <0.001
Adjusted for sex, previous myocardial infarction, left ventricular ejection fraction <40%, C reactive protein >3 mg/l, diabetes, peak troponin, and
GRACE (Global Registry of Acute Coronary Events) score.
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that the level of risk in older patients derived from the
concentration of NT-proBNP was very similar to that
found in the overall population (hazard ratio 2.34 v
2.55) (table 2). In multivariate analysis, NT-proBNP
remained strongly associated with the outcome,
beyond traditional risk factors including creatinine
clearance and left ventricular ejection fraction, in
each age group except the youngest one (<54 years)
(P=0.29). Moreover, addition of NT-proBNP signifi-
cantly improved the performance of the statistical
model in the overall study population (−2log likeli-
hood 3179.58 v 3099.74, P<0.001)and in each quarter
includingtheupperone(1523.52v 1495.01,P<0.001).
To further investigate the independent discriminative
value of NT-proBNP compared with the GRACE
score,wedidadiagonalstratificationusingthemedian
value of the GRACE score and NT-proBNP in older
patients (upper quarter) (figure). Such stratification
strikingly identified a high risk group—patients from
the higher NT-proBNP group and with a high risk
score—which was characterised by a risk of death of
almost 50% at one year (figure). We found no signifi-
cant interaction between age and NT-proBNP for the
outcome in any age categories.
DISCUSSION
Majorrandomisedandobservationalstudieshavepro-
videdconsistentobservationsthatconcentrationsofB-
typenatriureticpeptideorNT-proBNPareusefultools
for risk stratification of patients with acute myocardial
infarction, particularly for predicting mortality.
8918-22
These peptides have a powerful prognostic value
both in patients without a history of heart failure and
in those without clinical signs of left ventricular dys-
functiononadmissionor duringthe hospital stay. Gal-
vani et al’s meta-analysis showed that the prognostic
value of natriuretic peptides is similar for short term
and long term prediction, when peptides were mea-
sured at the first contact with the patient or during the
hospital stay, for B-type natriuretic peptide or NT-
proBNP, and in patients with ST segment elevation
myocardial infarction or non-ST segment elevation
myocardial infarction.
23 However, none of these stu-
dies specifically assessed the predictive value of the
natriuretic peptide in elderly people and some even
excluded older patients.
9 In the light of the increasing
prevalence of acute myocardial infarction and the
increasing age of patients, understanding the relation
between age and NT-proBNP concentrations is a key
factor in the successful stratification of risk in acute
myocardial infarction. This is one of the first studies
to specifically assess the prognostic value of NT-
proBNP in older patients with myocardial infarction.
Increased NT-proBNP and older people
A striking increase in mean and upper centile values
for NT-proBNP with age has been reported in healthy
volunteers.
2425Aftermultivariateadjustment,a10year
increase in age was associated with a 1.4-fold increase
in pro-peptide concentration.
24 In animal studies, an
increase in natriuretic peptide gene expression has
been documented with advancing age.
26 Furthermore,
the increase in natriuretic peptide concentrations with
age may reflect a higher prevalence of subclinical car-
diac disease in healthy older people. Our study shows
that sex, renal function, and left ventricular ejection
fractionarethe majorcontributorstoelevatedconcen-
trations of the pro-peptide in patients with acute myo-
cardial infarction. Our data also suggest that
comorbidities such as diabetes and hypertension
have little impact on NT-proBNP in older people
with myocardial infarction.
Secretion of natriuretic peptides is markedly regu-
lated by wall tension of the left ventricles,
27 and B-
type natriuretic peptide concentrations are indicators
of left ventricular systolic function after myocardial
infarction.
28 The mechanisms whereby sex and renal
function influence circulating concentrations of NT-
proBNP remain unclear. Clinical studies have
reporteda decrease in the clearance of natriuretic pep-
tidesfromplasmainolderpatients,evenintheabsence
of renal dysfunction.
29 Impairment of non-renal clear-
ancemechanisms,suchasplateletassociatedclearance
receptors,maycontributetothehigherconcentrations
seen in older people.
30 The proportion of women was
higher in the upper age quarter in our study, and the
proportion of women had an independent impact on
pro-peptide concentrations whatever the age group.
The physiological basis for this sex related difference
isunclear.Astimulatoryeffectoffemalesexhormones
has been reported in experimental studies,
31 and pro-
duction of B-type natriuretic peptide may be sensitive
to oestrogen regulation.
32
NT-proBNP and mortality
Ourdatafrompatientsinroutineclinicalpracticeshow
that the concentration of NT-proBNP on admission
remains a useful tool for risk stratification, even in
olderpatients.Fewdataareavailableontheprognostic
value of NT-proBNP in elderly patients with acute
myocardial infarction. Drewniak et al, in a small
study specifically investigating older patients (>
NT-proBNP concentration
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infarction.NT-proBNPconcentrationsweremeasured
within the first 48 hours of admission to hospital, as
well as left ventricular ejection fraction, Killip class,
and a six minute walk test. The authors found a strong
relationbetweenNT-proBNPconcentrationsandclin-
ical outcomes at six months in such patients.
14 Multi-
variateanalysisshowedthatageandNT-proBNPwere
independent predictors of six month mortality. How-
ever,confoundingfactorssuchascreatinineclearance,
history of myocardial infarction, troponins, and the
GRACE score were not included as covariates in the
multivariate analysis.
Despiteadramaticincrease(byafactoroftwo)inthe
risk of death, our study based on a large population
supports the concept that NT-proBNP in older people
(>77 years) retains the same prognostic capacity as in
younger patients. In multivariate analysis, NT-
proBNP concentration was independently associated
with mortality, with a hazard ratio above two in each
age group except in younger patients (<54 years).
However, the small number of deaths (n=25) in this
age group may have resulted in insufficient statistical
power. Further studies in a larger population are
neededtoquantifythepredictivevalueofNT-proBNP
in young patients with myocardial infarction. NT-
proBNP has incremental prognostic value in older
patients,beyondtraditionalriskmarkerssuchastropo-
nin, GRACE score, C reactive protein, left ventricular
ejection fraction, diabetes, and renal function, and
even in the presence of high levels of the pro-peptide.
To the best of our knowledge, only one study has ana-
lysed the complementary predictive value of B-type
natriuretic peptide and GRACE score in patients
admitted to the emergency department for chest pain
suggestiveofacutecoronarysyndrome.
33Inthisstudy,
hightroponinconcentrationdidnotpredictoutcomes.
Thesedataareconsistentwithourfindingsshowingthe
lack of an independent predictive value of troponin.
The high incidence of myocardial infarction and
increased mortality in the elderly population has iden-
tified this age group as one in which effective acute
treatment strategies would have the greatest potential
impactin achievinga reductionin mortality. Ourfind-
ingsclearlyindicatethatasingleNT-proBNPmeasure-
ment in the early hours after admission would be
helpful in defining risk in older patients. Despite
increased concentrations of NT-proBNP in older
patientswithacutemyocardialinfarction,NT-proBNP
retained its prognostic capacity and correlated signifi-
cantly with one year cardiovascular mortality.
Study limitations
A limitation of this study is that the population of the
RICO survey is almost exclusively white, and thus we
wereunabletoinvestigatetheinfluenceofethnicityon
NT-proBNP.Giventhestrengthofthefindings,adjust-
ment for these factors would be unlikely to change the
main conclusion of our work. However, the cut-off
points determined from this study may not be applic-
able in other community cohorts.
Conclusions
In this large contemporary non-selected cohort of
patients with myocardial infarction, we have shown
for the first time that NT-proBNP concentration has
incremental prognostic value even in older patients,
above and beyond GRACE risk score and traditional
biomarkers afteracute myocardial infarction. Inspired
bytheuseofB-typenatriureticpeptidesinthemanage-
ment of heart failure,
34 a very important question is
nowemergingastowhetherB-typenatriureticpeptide
concentrations should influence management of
patients with acute myocardial infarction.
35 The rapid
and accurate assessment of risk is crucial for effective
management of such patients. Moreover, patients at
high risk, such as elderly people, may derive maximal
benefit from an early aggressive treatment strategy.
22
Among the developed risk scores, the GRACE risk
score, driving more than 90% of the prognostic infor-
mation,iscurrentlyconsideredtobethebestriskscore
in acute coronary syndromes. However, prospective
studies specifically assessing the incremental value,
beyond GRACE risk score, of biomarkers such as
NT-proBNP are urgently needed.
36 In this context,
our data further support the potential interest of clini-
cal trials specifically investigating NT-proBNP mea-
surement as a guide to current treatment strategies, as
well as novel strategies, in older patients with acute
myocardial infarction.
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